STOCK TITAN

[144] Rocket Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing for Rocket Pharmaceuticals, Inc. (RCKT) shows a proposed sale of 1,004 common shares through Fidelity Brokerage Services with an aggregate market value of $3,077.46, planned for 08/18/2025 on NASDAQ. The shares were acquired by the filer on 08/14/2025 through restricted stock vesting as compensation. The filing also discloses two recent sales by the same person in the prior three months: 587 shares sold on 05/20/2025 for $3,783.80 and 12,109 shares sold on 08/14/2025 for $36,553.44. The notice includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider sale notification; small-dollar proposed sale following restricted stock vesting and prior recent dispositions.

The filing documents a prospectus-exempt sale under Rule 144 of 1,004 common shares valued at $3,077.46 and states the shares were obtained via restricted stock vesting on 08/14/2025 as compensation. The filer previously sold 587 and 12,109 shares in the past three months, generating gross proceeds of $3,783.80 and $36,553.44 respectively. From a compliance viewpoint, the form provides required broker and acquisition details and the signer’s attestation about material nonpublic information.

TL;DR: Filing is a standard disclosure of insider sales and compensation-related share vesting; procedural compliance appears met.

The document identifies the broker, sale timing, acquisition method (restricted stock vesting), and includes the mandatory representation regarding undisclosed material information. It also lists recent sales by the same person during the three-month lookback. The disclosure content aligns with Rule 144 reporting requirements and provides transparency about insider stock movements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Rocket Pharmaceu

NASDAQ:RCKT

RCKT Rankings

RCKT Latest News

RCKT Latest SEC Filings

RCKT Stock Data

376.61M
104.03M
3.27%
90.63%
14.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK